Pfizer Inc. (PFE)
28.41
+0.45
(+1.61%)
USD |
NYSE |
Aug 31, 13:15
Pfizer Total Long Term Debt (Quarterly) : 63.10B for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 63.10B |
| March 31, 2026 | 64.43B |
| December 31, 2025 | 66.93B |
| September 30, 2025 | 61.66B |
| June 30, 2025 | 61.75B |
| March 31, 2025 | 61.39B |
| December 31, 2024 | 63.44B |
| September 30, 2024 | 61.75B |
| June 30, 2024 | 61.25B |
| March 31, 2024 | 62.31B |
| December 31, 2023 | 66.42B |
| September 30, 2023 | 63.31B |
| June 30, 2023 | 64.92B |
| March 31, 2023 | 35.27B |
| December 31, 2022 | 38.04B |
| September 30, 2022 | 35.20B |
| June 30, 2022 | 35.57B |
| March 31, 2022 | 35.92B |
| December 31, 2021 | 40.34B |
| September 30, 2021 | 38.91B |
| June 30, 2021 | 39.04B |
| March 31, 2021 | 39.02B |
| December 31, 2020 | 40.24B |
| September 30, 2020 | 51.93B |
| June 30, 2020 | 52.01B |
| Date | Value |
|---|---|
| March 31, 2020 | 36.62B |
| December 31, 2019 | 38.46B |
| September 30, 2019 | 39.51B |
| June 30, 2019 | 39.33B |
| March 31, 2019 | 41.25B |
| December 31, 2018 | 37.68B |
| September 30, 2018 | 37.91B |
| June 30, 2018 | 33.20B |
| March 31, 2018 | 36.59B |
| December 31, 2017 | 37.08B |
| September 30, 2017 | 37.58B |
| June 30, 2017 | 37.26B |
| March 31, 2017 | 39.62B |
| December 31, 2016 | 35.62B |
| September 30, 2016 | 30.44B |
| June 30, 2016 | 30.46B |
| March 31, 2016 | 27.82B |
| December 31, 2015 | 32.54B |
| September 30, 2015 | 34.00B |
| June 30, 2015 | 26.73B |
| March 31, 2015 | 29.37B |
| December 31, 2014 | 34.55B |
| September 30, 2014 | 31.67B |
| June 30, 2014 | 32.27B |
| March 31, 2014 | 27.65B |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Johnson & Johnson | 37.34B |
| Eli Lilly & Co. | 49.62B |
| Merck & Co., Inc. | 51.08B |
| Bristol Myers Squibb Co. | 44.59B |
| Viatris, Inc. | 13.51B |